Paul Brooks (Oxford Genetics Ltd. (Oxgene))

Brooks, Paul (CN Innovations 202212– CEO joined as CBO 5/22 before Horizon Discovery + Oxford Genetics + Sigma-Aldrich)

	Organisation	Oxford Genetics Ltd. (Oxgene)
	Former/major organisation	Horizon Discovery Ltd.
	Group	PerkinElmer (Group)
	Product	PhysioMimix® Organs-on-Chips system
	Product 2	BIOTECH

CN Bio Innovations Ltd.. (12/19/22). "Press Release: CN Bio Appoints Dr Paul Brooks as Chief Executive Officer". Cambridge.

> Key strategic appointment as the Company enters next phase of commercial growth and global expansion of its products and services

> Former CEO, Dr David Hughes, appointed to Scientific Advisory Board

CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced the appointment of Dr Paul Brooks, formerly the Company’s Chief Business Officer, to the position of CEO with immediate effect. Former CEO, Dr David Hughes, will continue to work with the company in a consultative role within the Company’s Scientific Advisory Board.

Paul’s appointment signifies the next stage of CN Bio’s commercial development. He will be focused on driving the Company’s global expansion plans, to reach new customers and create value for shareholders. Having joined the Company as Chief Business Officer in May 2022, Paul was responsible for shaping CN Bio’s commercial business, expansion strategy and overseeing accelerated growth of the Company's PhysioMimix™ OOC range of MPS, consumables, kits and services. In this time, CN Bio also doubled the laboratory space dedicated to its contract research services, in response to rising demand for the Company’s OOC expertise by pharma and biotech companies.

With over 25 years’ experience in the Life Science sector, Paul is an experienced C-suite level executive; prior to joining CN Bio he was Head of Business Operations & Managing Director for PerkinElmer’s Horizon Discovery, where he led the strategic and operational transformation of its business units. Throughout his career, Paul has supported successful growth across a broad range of companies, including Head of Discovery Research Services & General Manager at Sigma-Aldrich (now Merck KGaA), and as Chief Commercial Officer & Executive Director and Board member at Oxford Genetics, driving its transformation from start-up company to commercialisation. Paul completed his PhD in Molecular Biology from the University of Manchester Institute of Science and Technology and holds an MBA from Nottingham Business School.

As part of the Scientific Advisory Board, CN Bio will continue to benefit from Dr David Hughes’ domain expertise and extensive technical bioengineering background. In this consultative role, Dr Hughes will remain involved in the future development of CN Bio’s product and service portfolio.

Dr Paul Brooks, CEO at CN Bio, said: “I would like to thank David for his leadership of CN Bio through a transformational time, and I look forward to working with him as we begin to fully exploit our incredible innovation engine. I am honoured to be appointed CEO at a pivotal time in the Company’s, and the industry’s, evolution, as the value of well-characterised microphysiological systems is increasingly recognised to revolutionise therapeutic programmes. As we enter 2023, CN Bio is well positioned to build upon its successes so far and enter this exciting next stage of commercial growth and expansion.”

Dr David Hughes, previously CEO, CN Bio, commented: “Since joining the team, Paul has been a driving force for initiating the next phase of CN Bio’s development. His breadth of industry experience, paired with extensive technical expertise, is a huge asset to the Company as CEO, and I am confident that he will successfully continue our mission to transform drug discovery. My sincere thanks go to the team, who I have worked alongside for 12 years, and I now look forward to supporting CN Bio’s innovation and growth in an advisory role.”

ENDS

Notes to Editors

Image: Dr Paul Brooks, CEO, CN Bio
For a high-resolution image please contact Zyme Communications.

For further information please contact:

Zyme Communications
Lily Jeffery
Tel: +44(0)7891477378
Email: lily.jeffery@zymecommunications.com

CN Bio
Dr Sarah Payne, Marketing Manager
Email: sarah.payne@cn-bio.com

To opt-out from receiving press releases from Zyme Communications please e-mail info@zymecommunications.com. To view our privacy policy, please click here.

About CN Bio https://cn-bio.com/

CN Bio is a leading organ-on-a-chip (OOC) company that offers a portfolio of products and services to optimise the accuracy and efficiency of bringing new medicines to market; providing significant savings in cost and time to drug discovery and development pipelines. With more than a decade of research and development experience in multi-organ microphysiology, CN Bio aims to transform the way human-relevant pre-clinical data is generated through the development of the most complete model of the human “Body-on-a-Chip” in the laboratory.

The Company’s range of lab-benchtop PhysioMimix™ microphysiological systems (MPS) enable researchers to model human biology in the lab through rapid and predictive 3D human tissue-based studies that harness microfluidic technology to provide nutrients and mimic blood flow. The technology bridges the gap between traditional cell culture and human studies, advancing towards the simulation of human biological conditions to support the accelerated and more efficient development of new therapeutics, whilst reducing the dependence on animal model usage.

CN Bio’s MPS support researchers that require reliable, data-rich, in vitro studies, to uncover novel mechanistic insights into a broad range of biological processes across healthy and diseased cell-types, in addition to identifying novel therapeutic targets and investigating drug efficacy, pharmacokinetics and potential toxicity.

The Company’s next-generation OOC assays span a range of organ types, including lung, liver and gut. Single organs can be linked together into multi-organ systems to simulate processes such as drug absorption and metabolism, or to understand interactions between organs, such as inflammation.

Harnessing these assays, its portfolio of MPS, 3D validated cells, compatible consumable plates and research services have been developed to address drug development bottlenecks across a range of therapeutic areas, including metabolic and infectious diseases, oncology, and inflammation.

CN Bio’s technology is developed internally and licensed from Massachusetts Institute of Technology (MIT), Northeastern University and Vanderbilt University, and has been successfully adopted by numerous pharma and academic partners, including recognition from the US FDA.

CN Bio’s headquarters and laboratories are based in Cambridge, UK, with an international network of distributors.